PLRX
Pliant Therapeutics, Inc.
Price Chart
Latest Quote
$1.15
-0.01 (-1.29%)
Current Price
| Previous Close | $1.16 |
| Open | $1.17 |
| Day High | $1.18 |
| Day Low | $1.15 |
| Volume | 35,273 |
Stock Information
| Shares Outstanding | 61.92M |
| Total Debt | $28.78M |
| Cash Equivalents | $170.89M |
| Net Income | $-113.22M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $70.90M |
| EPS (TTM) | $-1.85 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-70.28M |
| Income | $-113.22M |
| Book/sh | $2.67 |
| Cash/sh | $2.76 |
| Employees | 49 |
Financial Ratios
| Quick Ratio | 16.50 |
| Current Ratio | 16.89 |
| Debt/Eq | 17.43 |
Returns & Margins
| ROA | -25.79% |
| ROE | -53.62% |
Ownership
| Insider Ownership | 2.35% |
| Institutional Ownership | 81.95% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.20 |
| P/B | 0.43 |
Analyst Data
| Recommendation | none |
| Target Price | $2.67 |
Technical Indicators
| SMA20 | $1.18 |
| SMA50 | $1.21 |
| SMA200 | $1.36 |
| RSI | 40.68 |
| ATR | 0.0498 |
| Shares Float | 60.23M |
| Short Float | 5.68% |
| Short Ratio | 8.02 |
| Rel Volume | 0.08 |
Performance History
| Week | +1.33% |
| Month | -4.58% |
| Quarter | -11.24% |
| 6 Months | -6.15% |
| YTD | -8.40% |
| Year | -12.60% |
| 3 Years | -95.29% |
| 5 Years | -96.52% |
| 10 Years | -94.62% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $1.14 | 35,273 |
| 2026-06-18 | $1.16 | 472,900 |
| 2026-06-17 | $1.18 | 303,300 |
| 2026-06-16 | $1.19 | 513,400 |
| 2026-06-15 | $1.14 | 375,200 |
| 2026-06-12 | $1.13 | 207,200 |
| 2026-06-11 | $1.14 | 491,600 |
| 2026-06-10 | $1.16 | 345,500 |
| 2026-06-09 | $1.19 | 279,800 |
| 2026-06-08 | $1.15 | 169,400 |
| 2026-06-05 | $1.15 | 409,100 |
| 2026-06-04 | $1.17 | 321,100 |
| 2026-06-03 | $1.18 | 1,589,800 |
| 2026-06-02 | $1.16 | 986,100 |
| 2026-06-01 | $1.20 | 756,100 |
| 2026-05-29 | $1.26 | 314,900 |
| 2026-05-28 | $1.25 | 210,400 |
| 2026-05-27 | $1.24 | 216,700 |
| 2026-05-26 | $1.24 | 694,100 |
| 2026-05-22 | $1.21 | 212,100 |
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avÃ8 and avÃ1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
đ° Latest News
Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference
MarketBeat âĸ 2026-03-01T15:39:48Z
3 Promising Penny Stocks With Market Caps Under $500M
Simply Wall St. âĸ 2025-10-17T12:05:06Z
Align downgraded, NetEase upgraded: Wall Street's top analyst calls
The Fly âĸ 2025-10-10T13:36:17Z
Penny Stocks To Watch With Market Caps Under $700M
Simply Wall St. âĸ 2025-09-08T18:04:55Z
3 Promising Penny Stocks With Market Caps Under $200M
Simply Wall St. âĸ 2025-07-15T18:09:06Z
Pliant halts bexotegrast development for IPF after trial results
Clinical Trials Arena âĸ 2025-06-30T11:43:56Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $1,580,000 | $9,685,000 |
| Operating Revenue | $0 | $0 | $1,580,000 | $9,685,000 |
| Expenses | ||||
| Interest Expense | $2,559,000 | $3,024,000 | $1,267,000 | $791,000 |
| Total Expenses | $156,373,000 | $228,365,000 | $185,725,000 | $136,885,000 |
| Other Income Expense | $-1,828,000 | - | - | - |
| Net Non Operating Interest Income Expense | $8,857,000 | $18,061,000 | $22,809,000 | $3,879,000 |
| Interest Expense Non Operating | $2,559,000 | $3,024,000 | $1,267,000 | $791,000 |
| Operating Expense | $156,373,000 | $228,365,000 | $185,725,000 | $136,885,000 |
| General And Administrative Expense | $47,216,000 | $59,055,000 | $57,928,000 | $39,949,000 |
| Total Other Finance Cost | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-149,344,000 | $-210,304,000 | $-161,336,000 | $-123,321,000 |
| Net Interest Income | $8,857,000 | $18,061,000 | $22,809,000 | $3,879,000 |
| Interest Income | $11,416,000 | $21,085,000 | $24,076,000 | $4,670,000 |
| Normalized Income | $-147,516,000 | $-210,304,000 | $-161,336,000 | $-123,321,000 |
| Net Income From Continuing And Discontinued Operation | $-149,344,000 | $-210,304,000 | $-161,336,000 | $-123,321,000 |
| Total Operating Income As Reported | $-156,373,000 | $-228,365,000 | $-184,145,000 | $-127,200,000 |
| Net Income Common Stockholders | $-149,344,000 | $-210,304,000 | $-161,336,000 | $-123,321,000 |
| Net Income | $-149,344,000 | $-210,304,000 | $-161,336,000 | $-123,321,000 |
| Net Income Including Noncontrolling Interests | $-149,344,000 | $-210,304,000 | $-161,336,000 | $-123,321,000 |
| Net Income Continuous Operations | $-149,344,000 | $-210,304,000 | $-161,336,000 | $-123,321,000 |
| Pretax Income | $-149,344,000 | $-210,304,000 | $-161,336,000 | $-123,321,000 |
| Special Income Charges | $-1,828,000 | $0 | - | - |
| Interest Income Non Operating | $11,416,000 | $21,085,000 | $24,076,000 | $4,670,000 |
| Operating Income | $-156,373,000 | $-228,365,000 | $-184,145,000 | $-127,200,000 |
| Per Share | ||||
| Diluted EPS | $-2.43 | $-3.47 | $-2.75 | $-2.94 |
| Basic EPS | $-2.43 | $-3.47 | $-2.75 | $-2.94 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-143,261,000 | $-205,155,000 | $-158,228,000 | $-120,707,000 |
| Total Unusual Items | $-1,828,000 | $0 | - | - |
| Total Unusual Items Excluding Goodwill | $-1,828,000 | $0 | - | - |
| Reconciled Depreciation | $1,696,000 | $2,125,000 | $1,841,000 | $1,823,000 |
| EBITDA (Bullshit earnings) | $-145,089,000 | $-205,155,000 | $-158,228,000 | $-120,707,000 |
| EBIT | $-146,785,000 | $-207,280,000 | $-160,069,000 | $-122,530,000 |
| Diluted Average Shares | $61,366,887 | $60,538,639 | $58,719,083 | $42,015,908 |
| Basic Average Shares | $61,366,887 | $60,538,639 | $58,719,083 | $42,015,908 |
| Diluted NI Availto Com Stockholders | $-149,344,000 | $-210,304,000 | $-161,336,000 | $-123,321,000 |
| Other Special Charges | $1,828,000 | - | - | - |
| Research And Development | $109,157,000 | $169,310,000 | $127,797,000 | $96,936,000 |
| Selling General And Administration | $47,216,000 | $59,055,000 | $57,928,000 | $39,949,000 |
| Other Gand A | $47,216,000 | $59,055,000 | $57,928,000 | $39,949,000 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $181,205,000 | $304,081,000 | $473,576,000 | $313,342,000 |
| Total Assets | $225,228,000 | $396,949,000 | $512,154,000 | $350,613,000 |
| Total Non Current Assets | $28,780,000 | $34,685,000 | $6,652,000 | $10,302,000 |
| Other Non Current Assets | $1,874,000 | $1,917,000 | $1,874,000 | $394,000 |
| Current Assets | $196,448,000 | $362,264,000 | $505,502,000 | $340,311,000 |
| Other Current Assets | $92,000 | $163,000 | $1,272,000 | $173,000 |
| Assets Held For Sale Current | $1,040,000 | $0 | - | - |
| Prepaid Assets | $3,549,000 | $4,075,000 | $6,988,000 | $5,807,000 |
| Receivables | $823,000 | $2,302,000 | $2,997,000 | $3,144,000 |
| Accrued Interest Receivable | $823,000 | $2,302,000 | $2,997,000 | $1,078,000 |
| Cash Cash Equivalents And Short Term Investments | $190,944,000 | $355,724,000 | $494,245,000 | $331,187,000 |
| Cash And Cash Equivalents | $45,445,000 | $71,188,000 | $63,234,000 | $33,685,000 |
| Taxes Receivable | - | - | $0 | $83,000 |
| Accounts Receivable | - | - | $0 | $1,983,000 |
| Debt | ||||
| Total Debt | $29,105,000 | $60,192,000 | $11,372,000 | $15,815,000 |
| Long Term Debt And Capital Lease Obligation | $27,658,000 | $59,650,000 | $10,054,000 | $13,358,000 |
| Current Debt And Capital Lease Obligation | $1,447,000 | $542,000 | $1,318,000 | $2,457,000 |
| Long Term Debt | - | $30,211,000 | $10,054,000 | $9,929,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $44,023,000 | $92,868,000 | $38,578,000 | $37,271,000 |
| Total Non Current Liabilities Net Minority Interest | $27,658,000 | $59,650,000 | $10,054,000 | $13,358,000 |
| Current Liabilities | $16,365,000 | $33,218,000 | $28,524,000 | $23,913,000 |
| Payables And Accrued Expenses | $6,620,000 | $21,522,000 | $18,164,000 | $14,256,000 |
| Payables | $480,000 | $5,960,000 | $4,531,000 | $1,580,000 |
| Accounts Payable | $480,000 | $5,960,000 | $4,531,000 | $1,580,000 |
| Non Current Deferred Liabilities | - | - | - | - |
| Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $181,205,000 | $304,081,000 | $473,576,000 | $313,342,000 |
| Total Equity Gross Minority Interest | $181,205,000 | $304,081,000 | $473,576,000 | $313,342,000 |
| Stockholders Equity | $181,205,000 | $304,081,000 | $473,576,000 | $313,342,000 |
| Gains Losses Not Affecting Retained Earnings | $-15,000 | $321,000 | $345,000 | $-1,958,000 |
| Other Equity Adjustments | $-15,000 | $321,000 | $345,000 | $-1,958,000 |
| Retained Earnings | $-859,396,000 | $-710,052,000 | $-499,748,000 | $-338,412,000 |
| Other | ||||
| Ordinary Shares Number | $61,449,290 | $60,860,838 | $59,921,002 | $48,941,254 |
| Share Issued | $61,449,290 | $60,860,838 | $59,921,002 | $48,941,254 |
| Tangible Book Value | $181,205,000 | $304,081,000 | $473,576,000 | $313,342,000 |
| Invested Capital | $181,205,000 | $334,292,000 | $483,630,000 | $323,271,000 |
| Working Capital | $180,083,000 | $329,046,000 | $476,978,000 | $316,398,000 |
| Capital Lease Obligations | $29,105,000 | $29,981,000 | $1,318,000 | $5,886,000 |
| Total Capitalization | $181,205,000 | $334,292,000 | $483,630,000 | $323,271,000 |
| Additional Paid In Capital | $1,040,610,000 | $1,013,806,000 | $972,973,000 | $653,707,000 |
| Capital Stock | $6,000 | $6,000 | $6,000 | $5,000 |
| Common Stock | $6,000 | $6,000 | $6,000 | $5,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $27,658,000 | $29,439,000 | $0 | $3,429,000 |
| Current Capital Lease Obligation | $1,447,000 | $542,000 | $1,318,000 | $2,457,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $8,298,000 | $11,154,000 | $9,042,000 | $7,200,000 |
| Current Accrued Expenses | $6,140,000 | $15,562,000 | $13,633,000 | $12,676,000 |
| Net PPE | $26,906,000 | $32,768,000 | $4,778,000 | $9,908,000 |
| Accumulated Depreciation | $-10,869,000 | $-10,807,000 | $-8,682,000 | $-6,841,000 |
| Gross PPE | $37,775,000 | $43,575,000 | $13,460,000 | $16,749,000 |
| Leases | $2,156,000 | $2,118,000 | $1,663,000 | $1,650,000 |
| Construction In Progress | $153,000 | $346,000 | $52,000 | $66,000 |
| Other Properties | $32,529,000 | $38,231,000 | $11,621,000 | $15,003,000 |
| Machinery Furniture Equipment | $2,937,000 | $2,880,000 | $124,000 | $30,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $145,499,000 | $284,536,000 | $431,011,000 | $297,502,000 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-128,710,000 | $-159,351,000 | $-117,282,000 | $-96,391,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-128,336,000 | $-155,503,000 | $-116,361,000 | $-94,631,000 |
| Cash Flow From Continuing Operating Activities | $-128,336,000 | $-155,503,000 | $-116,361,000 | $-94,631,000 |
| Operating Gains Losses | $1,784,000 | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-374,000 | $-3,848,000 | $-921,000 | $-1,760,000 |
| Investing Cash Flow | $134,290,000 | $140,340,000 | $-127,012,000 | $-150,204,000 |
| Cash Flow From Continuing Investing Activities | $134,290,000 | $140,340,000 | $-127,012,000 | $-150,204,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $570,000 | $3,207,000 | $275,252,000 | $217,561,000 |
| Financing Cash Flow | $-31,697,000 | $23,117,000 | $274,405,000 | $226,854,000 |
| Cash Flow From Continuing Financing Activities | $-31,697,000 | $23,117,000 | $274,405,000 | $226,854,000 |
| Net Common Stock Issuance | $570,000 | $3,207,000 | $275,252,000 | $217,561,000 |
| Common Stock Issuance | $570,000 | $3,207,000 | $275,252,000 | $217,561,000 |
| Net Other Financing Charges | - | - | $-847,000 | $-557,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-32,267,000 | $0 | - | - |
| Issuance Of Debt | $0 | $19,910,000 | $0 | $9,850,000 |
| Interest Paid Supplemental Data | $2,539,000 | $2,620,000 | $1,149,000 | $615,000 |
| End Cash Position | $46,927,000 | $72,670,000 | $64,716,000 | $33,684,000 |
| Beginning Cash Position | $72,670,000 | $64,716,000 | $33,684,000 | $51,665,000 |
| Changes In Cash | $-25,743,000 | $7,954,000 | $31,032,000 | $-17,981,000 |
| Net Issuance Payments Of Debt | $-32,267,000 | $19,910,000 | $0 | $9,850,000 |
| Net Long Term Debt Issuance | $-32,267,000 | $19,910,000 | $0 | $9,850,000 |
| Long Term Debt Payments | $-32,267,000 | $0 | - | - |
| Long Term Debt Issuance | $0 | $19,910,000 | $0 | $9,850,000 |
| Net Investment Purchase And Sale | $134,509,000 | $144,188,000 | $-126,091,000 | $-148,444,000 |
| Sale Of Investment | $337,913,000 | $355,473,000 | $456,978,000 | $177,272,000 |
| Purchase Of Investment | $-203,404,000 | $-211,285,000 | $-583,069,000 | $-325,716,000 |
| Net PPE Purchase And Sale | $-219,000 | $-3,848,000 | $-921,000 | $-1,760,000 |
| Sale Of PPE | $155,000 | $0 | - | - |
| Purchase Of PPE | $-374,000 | $-3,848,000 | $-921,000 | $-1,760,000 |
| Change In Working Capital | $-15,939,000 | $9,089,000 | $1,251,000 | $4,217,000 |
| Change In Other Current Liabilities | $-876,000 | $-820,000 | $-2,747,000 | $-2,258,000 |
| Change In Other Current Assets | $43,000 | $-43,000 | $0 | $201,000 |
| Change In Payables And Accrued Expense | $-17,647,000 | $5,235,000 | $5,750,000 | $6,553,000 |
| Change In Accrued Expense | $-12,167,000 | $3,807,000 | $2,781,000 | $7,904,000 |
| Change In Payable | $-5,480,000 | $1,428,000 | $2,969,000 | $-1,351,000 |
| Change In Account Payable | $-5,480,000 | $1,428,000 | $2,969,000 | $-1,351,000 |
| Change In Prepaid Assets | $2,541,000 | $4,717,000 | $-3,735,000 | $-294,000 |
| Other Non Cash Items | $3,277,000 | $3,451,000 | $2,390,000 | $1,858,000 |
| Stock Based Compensation | $26,234,000 | $37,626,000 | $44,483,000 | $22,598,000 |
| Amortization Of Securities | $3,956,000 | $2,510,000 | $-4,990,000 | $-1,806,000 |
| Depreciation Amortization Depletion | $1,696,000 | $2,125,000 | $1,841,000 | $1,823,000 |
| Depreciation And Amortization | $1,696,000 | $2,125,000 | $1,841,000 | $1,823,000 |
| Depreciation | $1,696,000 | $2,125,000 | $1,841,000 | $1,823,000 |
| Gain Loss On Sale Of PPE | $-44,000 | $0 | - | - |
| Net Income From Continuing Operations | $-149,344,000 | $-210,304,000 | $-161,336,000 | $-123,321,000 |
| Change In Receivables | - | $0 | $1,983,000 | $15,000 |
| Changes In Account Receivables | - | $0 | $1,983,000 | $15,000 |
Fetched: 2026-06-20